A detailed history of Ballentine Partners, LLC transactions in Exact Sciences Corp stock. As of the latest transaction made, Ballentine Partners, LLC holds 3,399 shares of EXAS stock, worth $179,841. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3,399
Holding current value
$179,841
% of portfolio
0.0%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 23, 2024

BUY
$42.43 - $70.83 $144,219 - $240,751
3,399 New
3,399 $231,000
Q2 2023

Jul 26, 2023

BUY
$62.68 - $95.05 $154,318 - $234,013
2,462 New
2,462 $231,000

Others Institutions Holding EXAS

About EXACT SCIENCES CORP


  • Ticker EXAS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 176,960,000
  • Market Cap $9.36B
  • Description
  • Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for...
More about EXAS
Track This Portfolio

Track Ballentine Partners, LLC Portfolio

Follow Ballentine Partners, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ballentine Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ballentine Partners, LLC with notifications on news.